Drug Profile
ALLO 501
Alternative Names: ALLO-501; Anti-CD19 AlloCAR T; Anti-CD19 CAR T cell therapy - Allogene TherapeuticsLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Cellectis
- Developer Allogene Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
- No development reported Follicular lymphoma
Most Recent Events
- 09 Dec 2023 Pooled adverse events data from the phase-I/II ALPHA-2 trial of cemacabtagene ansegedleucel and phase-I ALPHA trial of ALLO-501 trial in Diffuse large B cell lymphoma were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 15 Jun 2023 Pooled efficacy and safety data from phase I/II ALPHA-2 trial of ALLO 501A and phase I ALPHA trial of ALLO 501 trial in Non-Hodgkin's lymphoma released by Allogene Therapeutics
- 08 Jun 2023 Pooled efficacy and adverse events data from the phase-I/II ALPHA-2 trial of ALLO 501A and phase-I ALPHA trial of ALLO 501 trial in Non-Hodgkin's lymphoma were presented at the 28th Congress of the European Haematology Association (EHA-2023)